BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AstraZeneca PLC (AZN) to Cut 1,150 Sales Jobs in US


12/7/2011 11:30:50 AM

WILMINGTON, Del., Dec 07, 2011 (BUSINESS WIRE) -- AstraZeneca AZN -0.35% announced today that it will reduce its U.S. sales force by approximately 1,150 leadership positions and sales representatives as part of the company's ongoing strategy to operate its business more efficiently to best serve patients in the United States.

These changes, which were not included in previously announced efficiencies to the U.S. business, will account for roughly 24 percent of the company's sales organization in the United States. The impact of the changes will vary by geography and selling teams.

"These are difficult decisions that impact valued employees," said Rich Fante, President, AstraZeneca U.S. "The changes we are making, however, will help us deliver better results for our business and, most importantly, continue delivering on our mission of patient health."

Employees will have the option to self-identify to potentially leave the company. All decisions will be finalized by early February 2012.

This change to the U.S. sales force is incremental to the ongoing second phase of the company's restructuring program that was announced in January 2010. As a result, a discreet restructuring cost associated with today's announced changes, estimated at between $50 million to $100 million, will be charged in the fourth quarter 2011. Restructuring costs are excluded from the company's core financial measures, so this initiative has no impact on guidance for core earnings per share for 2011.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).

SOURCE: AstraZeneca


Read at Reuters
Read at BioSpace.com
Read at Philadelphia Inquirer
Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES